285 related articles for article (PubMed ID: 25584630)
21. Structure-based development of antagonists for chemokine receptor CXCR4.
Zhang C; Hou T; Feng Z; Li Y
Curr Comput Aided Drug Des; 2013 Mar; 9(1):60-75. PubMed ID: 22734712
[TBL] [Abstract][Full Text] [Related]
22. A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor.
Tan S; Li W; Li Z; Li Y; Luo J; Yu L; Yang J; Qiu M; Cheng H; Xu W; Jiang S; Lu L; Liu S; Ma W
Viruses; 2019 Sep; 11(9):. PubMed ID: 31540474
[TBL] [Abstract][Full Text] [Related]
23. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK
J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337
[TBL] [Abstract][Full Text] [Related]
24. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
25. Targeting CXCR4 in HIV cell-entry inhibition.
Steen A; Schwartz TW; Rosenkilde MM
Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
[TBL] [Abstract][Full Text] [Related]
26. Role of CXCR4 internalization in the anti-HIV activity of stromal cell-derived factor-1α probed by a novel synthetically and modularly modified-chemokine analog.
Dong CZ; Tian S; Madani N; Choi WT; Kumar S; Liu D; Sodroski JG; Huang Z; An J
Exp Biol Med (Maywood); 2011 Dec; 236(12):1413-9. PubMed ID: 22101518
[TBL] [Abstract][Full Text] [Related]
27. Penicillixanthone A, a marine-derived dual-coreceptor antagonist as anti-HIV-1 agent.
Tan S; Yang B; Liu J; Xun T; Liu Y; Zhou X
Nat Prod Res; 2019 May; 33(10):1467-1471. PubMed ID: 29258357
[TBL] [Abstract][Full Text] [Related]
28. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
29. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
30. Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.
Heon Lee I; Palombo MS; Zhang X; Szekely Z; Sinko PJ
Eur J Pharm Biopharm; 2019 May; 138():11-22. PubMed ID: 29894816
[TBL] [Abstract][Full Text] [Related]
31. [Originality of entry inhibitors].
Izopet J
Med Mal Infect; 2009 Oct; 39(10 Suppl 1):H1-4. PubMed ID: 19837343
[No Abstract] [Full Text] [Related]
32. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
[TBL] [Abstract][Full Text] [Related]
33. A novel small-molecule inhibitor of HIV-1 entry.
Heredia A; Latinovic OS; Barbault F; de Leeuw EP
Drug Des Devel Ther; 2015; 9():5469-78. PubMed ID: 26491257
[TBL] [Abstract][Full Text] [Related]
34. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
35. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies.
Zhou N; Luo Z; Luo J; Liu D; Hall JW; Pomerantz RJ; Huang Z
J Biol Chem; 2001 Nov; 276(46):42826-33. PubMed ID: 11551942
[TBL] [Abstract][Full Text] [Related]
36. Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors.
Ohashi N; Harada S; Mizuguchi T; Irahara Y; Yamada Y; Kotani M; Nomura W; Matsushita S; Yoshimura K; Tamamura H
ChemMedChem; 2016 Apr; 11(8):940-6. PubMed ID: 26891461
[TBL] [Abstract][Full Text] [Related]
37. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
[TBL] [Abstract][Full Text] [Related]
38. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.
Singh IP; Chauthe SK
Expert Opin Ther Pat; 2011 Feb; 21(2):227-69. PubMed ID: 21219250
[TBL] [Abstract][Full Text] [Related]
39. CD4 mimics targeting the mechanism of HIV entry.
Yamada Y; Ochiai C; Yoshimura K; Tanaka T; Ohashi N; Narumi T; Nomura W; Harada S; Matsushita S; Tamamura H
Bioorg Med Chem Lett; 2010 Jan; 20(1):354-8. PubMed ID: 19926478
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
Fujii N; Nakashima H; Tamamura H
Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
